Just to be clear, RJKirk bought into a previously existing company started in 2001 (Pipex Therapeutics) that went public through a reverse merger in 2008 (renamed Adeona) and basically languished as a penny stock, well prior to Kirks initial investment in 2012.
Quote from a 2013 article. "He has reinvented Synthetic Biologics, buying in and ousting management, reinvigorating the pipeline with skillful acquisitions, pulling in his team, and lending SYN researchers use of Intrexon labs and resources."
Quote from a 2014 article.
"Finally, in 2012, a new management team replaced the old, quickly reshaping the company and reselling it to investors to raise its value.
“We came in and ended up doing a deal with R.J. Kirk, who is CEO of Intrexon Corp. and one of the most prolific entrepreneur investors in the biotech industry,” says current CEO Jeffrey Riley. “The deal jump-started the company and enabled us to raise capital.” He says “repurposing” the company required choosing a new product focus and building a pipeline to pursue it. The new team selected the anti-infectives space, with a mission to develop novel biologics to treat or prevent serious problems in antibiotic therapy. SB’s lead product is meant to avoid the typical complications that arise when broadspectrum antibiotics attack the microbiome in the colon as collateral damage and allow the notorious C. diff bacteria to flourish there."
XON on the other hand was his IPO and company from the get go.
SYN is now a reflection of RJKirk. Yes, he is the power behind it.
News 
Market Data 
Discover 
AI
